RiverVest Venture Partners — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.
BiotechHealthtechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)inNeela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in
BoardSamuel Bjork(Director)inMonique Schiersing(Director)in
Board seatJohn McKearn· per SEC Form D
Co-investorsRoche Venture FundVivo Capital3x5 PartnersCodon CapitalDigitalis Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.